Trastuzumab down-regulates the expression of ERBB2 and prevents both cell proliferation and tumor formation29, while gefitinib inhibits the activity of tyrosine kinase EGFR to inhibit the progression of cell cycle and tumor formation by arresting receptor autophosphorylation and the signal transduction process30. The gene discussed is ERBB2; the disease is neoplasm.